Monitor tax reform issues, including House GOP Tax Reform Blueprint
Monitor legislative discussions on 21st Century Cures (H.R. 6) and Senate biomedical innovation bills; Oppose CMMI proposed rule for Medicare Part B drug payment model
Duration: January 1, 2013
to
December 31, 2016
General Issues: Taxation/Internal Revenue Code , Health Issues , Food Industry (Safety, Labeling, etc.) , Copyright/Patent/Trademark , Trade (Domestic & Foreign) , Budget/Appropriations
Spending: about $470,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2013: U.S. Senate, House of Representatives
Affiliated organizations: Biotechnology Industry Organization
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
G. Hunter Bates Chief of Staff, Office of Senator Mitch McConnell
Legal Counsel, Office of Senator Mitch McConnell
Chief Counsel for Senate Rules Committee
Lauren O'Brien Deputy Chief of Staff-Legislative Director, Rep. Geoff Davis
Legislative Director, Office of Rep. Geoff Davis
Legislative Assistant, Office of Rep. Geoff Davis
Legislative Correspondent, Office of Rep. Geoff Davis
Staff Assistant, Office of Rep. Geoff Davis
Intern, Office of Rep. Jim Sensenbrenner
Geoff Davis U.S. Representative
Gordon Hunter Bates n/a
G Hunter Bates n/a
Hunter Bates n/a
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
4th Quarter, 2016
Republic Consulting, LLC terminated an engagement in which they represented Biotechnology Industry Organization on Jan. 23, 2017.
Original Filing: 300857141.xml
Lobbying Issues
Monitor tax reform issues, including House GOP Tax Reform Blueprint
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative discussions on 21st Century Cures (H.R. 6) and Senate biomedical innovation bills; Oppose CMMI proposed rule for Medicare Part B drug payment model
Agencies Lobbied
U.S. Senate
3rd Quarter, 2016
In Q3, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $50,000. The report was filed on Oct. 19, 2016.
Original Filing: 300833670.xml
Lobbying Issues
Monitor tax reform issues, including House GOP Tax Reform Task Force blueprint; Monitor discussions regarding Treasury's IRC Section 385 proposed regulations
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor legislative discussions on 21st Century Cures (H.R. 6) and Senate biomedical innovation bills; Monitor S. 2912, Trickett Wendler Right to Try Act
Lobbying Issues
Support the Biotech Labeling Solutions Act (S. 764 as amended and signed into law P.L. 114-216)
Agencies Lobbied
U.S. House of Representatives
Type of Issue
Food Industry (Safety, Labeling, etc.)
2nd Quarter, 2016
In Q2, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $50,000. The report was filed on July 16, 2016.
Original Filing: 300810949.xml
Lobbying Issues
Monitor tax issues, including innovation box proposal, international tax reform, corporate integration, and House GOP Tax Reform Task Force blueprint; Capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures (H.R. 2179, PARTNER Act); Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Orphan Drug Tax Credit; Monitor discussions regarding Treasury's IRC Section 385 proposed regulations
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Prescription drug pricing; Prescription drug importation; Oppose CMMI proposed rule for Medicare Part B Drug Payment Model demo; Monitor legislative discussions on 21st Century Cures (H.R. 6) and Senate biomedical innovation bills
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support changes to inter partes review system (S. 1137, PATENT Act)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Support federal role in regulation of disclosure of food derived from biotechnology (S. 2609, The Biotech Labeling Solutions Act); Monitor labeling of genetically engineered animals
Type of Issue
Food Industry (Safety, Labeling, etc.)
Lobbying Issues
Monitor TPP discussions and share concerns re drug exclusivity provisions of TPP
Type of Issue
Trade (Domestic & Foreign)
1st Quarter, 2016
In Q1, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $40,000. The report was filed on April 20, 2016.
Original Filing: 300800293.xml
Lobbying Issues
Monitor tax issues, including innovation box proposal, international tax reform, and corporate integration; Capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures (H.R. 2179, PARTNER Act); Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Orphan Drug Tax Credit; Support inclusion of vaccines in H.R. 3539, Reinvigorating Antibiotic and Diagnostic Innovation Act of 2015
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Prescription drug pricing; Prescription drug importation; Oppose CMMI proposed rule for Medicare Part B Drug Payment Model demo; Monitor Senate Finance activity on biomedical innovation bills
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support changes to inter partes review system (S. 1137, PATENT Act)
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor labeling of food derived from biotechnology (Support S. 2609, The Biotech Labeling Solutions Act); Monitor labeling of genetically engineered animals
Type of Issue
Food Industry (Safety, Labeling, etc.)
4th Quarter, 2015
In Q4, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on Jan. 19, 2016.
Original Filing: 300777025.xml
Lobbying Issues
Monitor tax reform (including patent box proposal) and tax extenders (H.R. 2029); capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures (H.R. 2179, PARTNER Act); Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; production tax credit for renewable chemicals; Orphan Drug Tax Credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor consideration of reconciliation bill (H.R. 3762) and amendments
Lobbying Issues
Prescription drug pricing; Prescription drug importation
Lobbying Issues
Support changes to inter partes review system in H.R. 9, Innovation Act and S. 1137, PATENT Act
Type of Issue
Copyright/Patent/Trademark
3rd Quarter, 2015
In Q3, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on Oct. 19, 2015.
Original Filing: 300757987.xml
Lobbying Issues
Monitor tax reform (including patent box proposal) and tax extenders; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures (H.R. 2179, PARTNER Act); Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; production tax credit for renewable chemicals; Orphan Drug Tax Credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor 21st Century Cures Act (H.R. 6) and pay-fors; Monitor DME infusion drug issues; Monitor Orphan Drug Fairness Act (S. 1906)
Agencies Lobbied
U.S. Senate
Lobbying Issues
Support changes to inter partes review system in H.R. 9, Innovation Act and S. 1137, PATENT Act; Support Costello-Peters letter re: IPR changes to H.R. 9
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
2nd Quarter, 2015
In Q2, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on July 20, 2015.
Original Filing: 300746477.xml
Lobbying Issues
Monitor tax reform and tax extenders; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures (H.R. 2179, PARTNER Act); Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; production tax credit for renewable chemicals; Orphan Drug Tax Credit
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor H.R. 2, Medicare Access and CHIP Reauthorization Act of 2015; Encourage FDA reform to enhance patient access to life-enhancing drugs; Monitor 21st Century Cures Act (H.R. 6); Support changes to H.R. 2581/H.R. 2570 to improve DME infusion drug provision
Agencies Lobbied
U.S. Senate
Lobbying Issues
Monitor developments re: trade promotion authority legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Support changes to inter partes review system in H.R. 9, Innovation Act and S. 1137, PATENT Act
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
1st Quarter, 2015
In Q1, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on April 20, 2015.
Original Filing: 300723523.xml
Lobbying Issues
Monitor tax reform and tax extenders; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; production tax credit for renewable chemicals.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Monitor developments re: trade promotion authority legislation
Agencies Lobbied
U.S. Senate
Type of Issue
Trade (Domestic & Foreign)
Lobbying Issues
Monitor discussion around replacement of Sustainable Growth Rate formula; monitor language striking non-interference clause under Medicare
Agencies Lobbied
U.S. Senate
Lobbying Issues
Promote balanced patent reform
Agencies Lobbied
U.S. Senate
Type of Issue
Copyright/Patent/Trademark
Lobbying Issues
Monitor consideration of Budget Resolution (S.Con.Res.11)
4th Quarter, 2014
In Q4, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on Jan. 16, 2015.
Original Filing: 300698512.xml
Lobbying Issues
Monitor tax reform and tax extenders; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Start Up Jobs and Innovation Act (S.1658).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
3rd Quarter, 2014
In Q3, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on Oct. 16, 2014.
Original Filing: 300678035.xml
Lobbying Issues
Monitor tax reform, tax extenders, and corporate inversions; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Start Up Jobs and Innovation Act (S.1658).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
340B Drug Pricing Program
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2014
In Q2, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on July 21, 2014.
Original Filing: 300666178.xml
Lobbying Issues
Monitor tax reform and tax extenders; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Start Up Jobs and Innovation Act (S.1658).
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2014
In Q1, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on April 21, 2014.
Original Filing: 300645437.xml
Lobbying Issues
Monitor tax reform, including discussion around Ways & Means tax draft; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Start Up Jobs and Innovation Act (S.1658)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
4th Quarter, 2013
In Q4, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on Jan. 17, 2014.
Original Filing: 300618477.xml
Lobbying Issues
Monitor budget discussions surrounding sequestration issues and the potential impact on healthcare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax reform; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Start Up Jobs and Innovation Act (S.1658)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
Lobbying Issues
Drug coverage under Part B and Part D; H.R. 2725/S.1413 FDA User Fee Protection Act
3rd Quarter, 2013
In Q3, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on Oct. 18, 2013.
Original Filing: 300598185.xml
Lobbying Issues
Monitor budget discussions surrounding sequestration issues and their potential impact on healthcare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax reform; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms.
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
2nd Quarter, 2013
In Q2, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $50,000. The report was filed on July 19, 2013.
Original Filing: 300578218.xml
Lobbying Issues
Monitor budget discussions surrounding sequestration and its potential impact on healthcare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part B drug coverage
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Tax reform; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Vaccine Injury Compensation Program/amending and extending vaccine excise tax (S. 391, H.R 475)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
In Q1, Republic Consulting, LLC lobbied for Biotechnology Industry Organization , earning $20,000. The report was filed on April 19, 2013.
Original Filing: 300554974.xml
Lobbying Issues
Monitor budget discussions surrounding sequestration and fiscal cliff issues and their potential impact on healthcare.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Medicare Part B drug coverage; Medicare Part D drug rebates; FDA and NIH funding; Independent Payment Advisory Board.
Agencies Lobbied
U.S. Senate
Lobbying Issues
Tax reform; capital formation tax policy; R&D tax credit; Section 469 R&D Partnership Structures; Section 382 Net Operating Loss rules; Section 1202 Capital Gains Reforms; Vaccine Injury Compensation Program/amending and extending vaccine excise tax (S. 391, H.R 475)
Agencies Lobbied
U.S. Senate
Type of Issue
Taxation/Internal Revenue Code
1st Quarter, 2013
Republic Consulting, LLC filed a lobbying registration on Jan. 23, 2013 to represent Biotechnology Industry Organization, effective Jan. 1, 2013.
Original Filing: 300543405.xml
Issue(s) they said they’d lobby about: Monitor budget discussions surrounding sequestration and fiscal cliff issues and their potential impact on healthcare.Support the repeal of IPAB. .
1st Quarter, 2013
Republic Consulting, LLC filed a lobbying registration on Jan. 18, 2013 to represent Bates Capitol Group, Inc. (on behalf of Biotechnology Industry Organization), effective Jan. 1, 2013.
Original Filing: 300533120.xml
Issue(s) they said they’d lobby about: Monitor budget discussions surrounding sequestration and fiscal cliff issues and their potential impact on healthcare.Support the repeal of IPAB. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...